Mirati Therapeutics Inc (MRTX) Drops 9.12% on January 19

Equities Staff |

Mirati Therapeutics Inc (MRTX) was one of the Russell 2000's biggest losers for Tuesday January 19 as the stock slid 9.12% to $23.22, a loss of $-2.33 per share. Starting at an opening price of $26.11 a share, the stock traded between $23.14 and $26.31 over the course of the trading day. Volume was 190,949 shares over 2,159 trades, against an average daily volume of 299,614 shares and a total float of 19.27 million.

The losses send Mirati Therapeutics Inc down to a market cap of $447.35 million. In the last year, Mirati Therapeutics Inc has traded between $52.00 and $18.64, and its 50-day SMA is currently $34.29 and 200-day SMA is $31.47.

Mirati Therapeutics Inc is a biopharmaceutical company that discovers, develops, and commercializes novel therapeutics with an initial focus on cancer and infectious diseases.

Mirati Therapeutics Inc is based out of San Diego, CA and has some 33 employees. Its CEO is Charles M. Baum.

For a complete fundamental analysis analysis of Mirati Therapeutics Inc, check out Equities.com’s Stock Valuation Analysis report for MRTX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Enertopia Corp

Enertopia Corp is engaged in the exploration of lithium in Nevada, USA. The Company's project includes Central Nevada Lithium Brine Projects.

Private Markets

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…